Aug 2026· Transplantation and Cellular Therapy· 0 citations· 66 references
Medicine
TL;DR
The key challenges inherent to CGT expansion are summarized, priority areas for coordinated action are identified, and a call to the field to address these needs with urgency and shared commitment is issued.
Abstract
Cellular and gene therapy (CGT) has fundamentally reshaped the treatment landscape for a growing range of malignant and non-malignant diseases. Yet the rapid expansion of CGT has also exposed critical institutional and system-level pressures, including constraints in infrastructure and workforce capacity, product manufacturing, patient access, regulatory and data reporting compliance, and long-term healthcare affordability and sustainability. These opportunities and challenges framed the joint plenary session sponsored by the American Society for Transplantation and Cellular Therapy (ASTCT), the Center for International Blood and Marrow Transplant Research (CIBMTR), and the European Society for Blood and Marrow Transplantation (EBMT) at the 2026 ASTCT-CIBMTR Tandem Meetings. This proceedings manuscript summarizes the key challenges inherent to CGT expansion, identifies priority areas for coordinated action, and issues a call to the field to address these needs with urgency and shared commitment.
This model advocates for decentralized, modular cleanroom facilities that integrate fully closed automated manufacturing platforms with risk-based quality management systems and emphasizes the strategic implementation of artificial intelligence (AI) and digital health tools—such as electronic batch records and predicti...
S. Cabrera-Salcedo, L. Parra-Lara, Mónica Fernandes-Pineda et al.· Frontiers in Public Health· 0 citations
The Regulation on the Administration of Clinical Research and Clinical Translational Application of New Biomedical Technologies, which entered into force in 2026, is interpreted, with a particular focus on its new dual-track regulatory framework that comprises a drug registration pathway and a new biomedical technology...
Wei Li, Zhen Qin, Xiu'e Wang et al.· Cytotherapy and Longevity· 0 citations
Recent developments and refinements in gene transfer and editing technologies for HSPCs are reviewed, while also discussing the critical limitations and hurdles to clinical translation, as recently presented at the New Investigator Committee Gene Therapy webinar.
Kohei Shiroshita, A. Stolz, C. Malouf et al.· Experimental Hematology· 0 citations
While chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies, there are significant hurdles to overcome, such as antigen escape, T-cell exhaustion, limited persistence in the body, severe toxicities, manufacturing complexity, high costs, and low effectiveness in...
Faizan-e-Mustaffa, Muhammad Shahbaz Aslam, Muhammad Junaid· Journal of the Egyptian Nati...· 0 citations
This review synthesizes contemporary breakthroughs in HSCT biology, technology, and clinical application, critically examines unresolved barriers, and highlights future directions, including Artificial Intelligence (AI)-driven predictive analytics, universal donor platforms, and equitable global access strategies.
M. Abah, Ovwigho Ugbede, O. C. et al.· DS Reviews of Research in Li...· 0 citations
This review summarizes the current landscape of POC CAR T-cell manufacturing, emphasizing clinical outcomes, economic sustainability, and regulatory considerations, and discusses emerging technologies, including allogeneic CAR T-cell platforms, artificial intelligence-driven manufacturing, and in vivo gene editing, tha...
Abdulrahman Nasiri, R. El Fakih, C. Chabannon et al.· Bone Marrow Transplantation· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
